Trialtrove-classified anticancer vaccine trials in non-small cell lung cancer: endpoints, attrition, and biomarker use
Year: 2026
Type: article
Abstract: Background Therapeutic cancer vaccines in non-small cell lung cancer (NSCLC) have been tested for three decades without regulatory approval. Three confirmatory-scale randomized trials reported negative results (vaccine biology), whereas later strategies were never tested at comparable scale (development practice). We characterize the latter. Methods We analyzed 207 interventional NSCLC trials classified by Trialtrove (April 2026) as evaluating anticancer vaccines, manually adjudicating free-text eligibility fields for immune-based criteria. The analyses were descriptive. Results Most trials were early phase (192/207, 92.8%); 78/207 (37.7%) specified no efficacy-oriented primary endpoint (68.2% of phase I, 10.3% of phase II and later). Of 46 terminated trials after enrolment, discontinuation for lack of efficacy ranged from 13.0% to 80.4%, which is too broad for definitive attribution. Immune-based selection was present in 52 trials but was largely limited to HLA restriction (42 trials) and PD-L1 thresholds (11 trials); no trial selected patients on baseline immune contexture. Conclusion Within Trialtrove-labelled vaccine trials in NSCLC, clinical-development architecture has been insufficient to distinguish biological failure from strategies that were never evaluated at a scale able to return a verdict. Combination and biomarker-enriched designs are increasingly common but have not yet demonstrated superior outcomes, accounting for four of the six terminations attributed to lack of efficacy in the cohort, all four of them in immuno-oncology combination trials; whether this reflects biological limitations, inadequate scale, or both cannot be determined from the available data. These findings may not represent the entire NSCLC vaccine field.
Source: Frontiers in Immunology
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7233798376
